In the second half of the year, the pharmaceutical sector four investment directions are optimistic

Since the first half of this year, the performance differentiation of pharmaceutical listed companies has become more obvious, pharmacies, CXO, vaccines and other sub-sectors continue to achieve rapid growth.
believes that the current pharmaceutical into the layout of good opportunities, four investment directions will be optimistic.
are innovative drugs, consumer, pharmacies, API and other high-boom sectors.
innovative drugs in terms of innovative drugs and their industrial chain, including innovative drugs, innovative devices, innovative vaccines, innovative testing and so on.
, innovative drugs, with the landing of the third batch of collection, means that the normalization of collection, the domestic innovative drug market will usher in new opportunities for development.
, the purchasing power of epidemic prevention materials has shifted from offline to online due to special periods, with surveys indicating that 68% of consumers will continue to buy epidemic prevention materials online after the outbreak.
expects the second half of the medical device to be strong.
innovation vaccine, the new version of the 2020 Drug Registration Management Measures provides strong policy support for the accelerated approval and listing of innovative vaccines, as well as the introduction of industry-related standards and the promotion of legislation, marking a new stage in China's vaccine industry and public health.
believes that the vaccine industry as a small and beautiful segment of the pharmaceutical sector is expected to usher in gold development.
Many biopharmaceutical companies have joined the team in the development of vaccines, including Watson Bio, Zhifei Bio, Kantai Bio, Hualan Bio, Changchun Gaoxin, Consino Bio, Kanghua Bio, Tibet Pharmaceuticals, Fosun Pharmaceuticals and other companies.
addition, in innovative testing, with the changing concept of people's health, the health monitoring industry will usher in greater room for development.
consumption in the field of pan-drug consumption, including independent consumption, consumption of traditional Chinese medicine.
industry expects the second half of the consumer growth probability will continue to improve, related enterprises face the industry concentration increase, consumption upgrade and other three opportunities.
Pharmacy chain medical institutions, including pharmacies, medical services, independent third-party testing institutions, since 2020, medical services and pharmacies have been affected to varying degrees, but from the industry's medium-term logic, the industry believes that the individual logic of the medical services sector and prescription outflow, integration of continuous pharmacy leaders have long-term investment value.
pharmaceutical specialty API and pharmaceutical distribution section.
Since this year, investors' attention to the globally competitive API varieties in China has continued to increase, with orders gradually concentrated on head enterprises, while the downstream demand for preparations has steadily increased, and then superimposed on the impact of the short-term outbreak, the second half of the specialty API enterprises are expected to usher in development opportunities.
pharmaceutical distribution sector is also favored by the industry.
recent years, the pharmaceutical industry has been changing, the market is more open, the first half of the sudden outbreak, although disrupting people's rhythm, but also for China's medical industry to accelerate the transformation of the opportunity.
drug distribution industry head effect is obvious, China National Pharmaceutical Holdings, China Resources Pharmaceuticals and Shanghai Pharmaceutical Holdings and other large-scale pharmaceutical circulation enterprises in the country's market share continues to expand, the industry competition is more intense.
the second half of this year, a number of giants are accelerating the layout of the pharmaceutical distribution sector.
For example, China National Pharmaceutical Holdings announced in August that the Board of Directors had amended the purpose of raising funds on August 21, 2020, and that the amount ofraised will be used by the Company and its subsidiaries to expand its pharmaceutical distribution, retail network and development of medical device business.